Celladon says heart treatment fails in trial

April 26, 2015 10:02 PM

13 0

NEW YORK (Reuters) - Celladon Corp said its heart failure gene therapy Mydicar failed to meet its primary and secondary endpoints in an important trial.

"We are surprised and very disappointed that Mydicar failed to meet the endpoints in the CUPID2 trial, and we are rigorously analyzing the data in an attempt to better understand the observed outcome," Celladon's chief executive, Krisztina Zsebo, said in a statement on Sunday.

Read more

To category page